Recent PSTX News
- Poseida Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/29/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:10 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/05/2024 08:33:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:10:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:24 PM
- Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 • PR Newswire (US) • 08/05/2024 08:05:00 PM
- Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum • PR Newswire (US) • 07/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:12:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:10:58 PM
- Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders • PR Newswire (US) • 06/03/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:11:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:06:16 PM
- Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 • PR Newswire (US) • 05/14/2024 08:05:00 PM
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting • PR Newswire (US) • 05/09/2024 01:00:00 PM
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology • PR Newswire (US) • 05/02/2024 01:30:00 AM
- Biotech Soars on Research Collaboration And License Agreement Release • AllPennyStocks.com • 05/01/2024 07:25:00 PM
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology • PR Newswire (US) • 05/01/2024 01:00:00 PM
- Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus • PR Newswire (US) • 04/17/2024 01:00:00 PM
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma • PR Newswire (US) • 04/08/2024 04:00:00 PM
- Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/01/2024 08:05:00 PM
- Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer • PR Newswire (US) • 03/25/2024 08:05:00 PM
- Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • PR Newswire (US) • 03/19/2024 08:05:00 PM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM